Invizyne Technologies Inc. (NASDAQ:IZTC - Get Free Report)'s stock price traded down 5.4% during trading on Thursday . The stock traded as low as $11.12 and last traded at $11.12. 1,303 shares were traded during mid-day trading, a decline of 97% from the average session volume of 37,647 shares. The stock had previously closed at $11.75.
Invizyne Technologies Stock Performance
The company has a fifty day moving average price of $14.01.
Institutional Investors Weigh In On Invizyne Technologies
A number of large investors have recently bought and sold shares of the business. Geode Capital Management LLC acquired a new stake in shares of Invizyne Technologies in the fourth quarter valued at $277,000. BNP Paribas Financial Markets acquired a new position in shares of Invizyne Technologies during the fourth quarter worth approximately $35,000. Finally, Citadel Advisors LLC bought a new stake in shares of Invizyne Technologies during the fourth quarter valued at approximately $456,000.
About Invizyne Technologies
(
Get Free Report)
Invizyne Technologies Inc is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc is based in Monrovia, CA.
Featured Stories
Before you consider Invizyne Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Invizyne Technologies wasn't on the list.
While Invizyne Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
